MyFinsight
Home
Blog
About
Sublocade
$238M
(22.05%↑ Y/Y)
Sublingual And Other
$57M
(9.62%↑ Y/Y)
Perseris
$5M
(-37.50%↓ Y/Y)
US
$300M
(17.19%↑ Y/Y)
Non Us
$43M
(-6.52%↓ Y/Y)
Net revenue
$343M
(13.58%↑ Y/Y)
Gross profit
$294M
(17.60%↑ Y/Y)
Cost of sales
$50M
(-3.85%↓ Y/Y)
Operating income
$160M
(122.22%↑ Y/Y)
Interest (income)
$3M
(-50.00%↓ Y/Y)
Total operating
expenses
$134M
Income before income
taxes
$160M
(158.06%↑ Y/Y)
Interest expense
$2M
(-86.67%↓ Y/Y)
Selling, general and
administrative
$122M
(-22.78%↓ Y/Y)
Research and development
$12M
(-42.86%↓ Y/Y)
Net income
$122M
(577.78%↑ Y/Y)
Income tax expense
$38M
(-13.64%↓ Y/Y)
Back
Back
Income Statement
indivior-logo-svg
Indivior Pharmaceuticals, Inc. (INDV)
indivior-logo-svg
source: myfinsight.com
Indivior Pharmaceuticals, Inc. (INDV)